The National Comprehensive Cancer Network and American Society of Clinical Oncology guidelines now include recommendations for germline testing in all patients with newly diagnosed PDAC, given the treatment implications for this group.26,27 We found that patients with BRCA or PALB2 mutant-associated pancreatic cancer may derive greater benefit from initiation of platinum-based chemotherapy in the first-line setting. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.